6533b86cfe1ef96bd12c824b

RESEARCH PRODUCT

The Assessment of Serum Concentrations of AGEs and Their Soluble Receptor (sRAGE) in Multiple Sclerosis Patients

Beata M Labuz-roszakKrystyna Tyrpień-golderBartłomiej KumaszkaBartosz TadeusiakAleksandra Damasiewicz-bodzek

subject

0301 basic medicinemedicine.medical_specialtyNeurosciences. Biological psychiatry. NeuropsychiatryDiseasemultiple sclerosisGastroenterologyArticlePathogenesis03 medical and health sciencesAGE0302 clinical medicineGlycationInternal medicineMedicineIn patientReceptoradvanced glycation end products; AGE; RAGE; sRAGE; multiple sclerosis; ELISAExpanded Disability Status Scalebusiness.industryadvanced glycation end productsGeneral NeuroscienceMultiple sclerosisSerum concentrationmedicine.diseaseRAGE030104 developmental biologyELISAbusiness030217 neurology & neurosurgeryRC321-571sRAGE

description

Background: Advanced glycation end products (AGEs) are involved in the pathogenesis of many diseases, including neurodegenerative diseases such as multiple sclerosis (MS). The aim of the study was to determine serum concentrations of AGEs and their soluble receptor (sRAGE) in MS patients and healthy controls and to investigate their possible influence on disease activity. Methods: Serum concentrations of AGE and sRAGE in patients with MS and healthy controls were determined by enzyme-linked immunosorbent assay (ELISA). Results: The mean serum AGE concentration in patients with MS was higher than in healthy controls, whereas the mean serum sRAGE concentration was lower than in the control group. However, the differences were not statistically significant. In MS patients, serum AGE and sRAGE concentrations did not differ significantly, depending on the duration of the disease and the Expanded Disability Status Scale (EDSS) score. Conclusions: Multiple sclerosis may be accompanied by disturbances of the AGE-sRAGE axis. However, further studies are warranted to confirm it. The duration of the disease and the degree of disability do not seem to affect the progression of the glycation process, particularly in the stable phase of the disease.

https://doi.org/10.3390/brainsci11081021